OncoMed halts enrollment in trials testing cancer drugs

June 13, 2014 2:01 PM

4 0

(Reuters) - OncoMed Pharmaceuticals Inc said it halted patient enrollment and dosing in early-stage trials testing two of its experimental cancer drugs, due to concerns of bone damage.

The company, whose stock fell about 25 percent in early trading, said it would propose lower and less frequent dosing for the studies, which test vantictumab and OMP-54F28 in combination with standard drugs.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page